IRCT20190127042504N1 IRCT 2019-02-22 Iran University of Medical Sciences Comparison of Bosentan and Sildenafil in the treatment of persistent pulmonary hypertension of the newborn Comparison of Bosentan and Sildenafil in the treatment of persistent pulmonary hypertension of the newborn 2017-06-16 anticipated 50 Complete https://irct.ir/trial/37115 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization of the formulation used in Excel software, the coupled numbers obtained in this table will be allocated to the drug A, namely, Bosentan and the individual numbers for the drug B, Sildenafil, Blinding description: The randomization is double blind. On the other hand, the neonates, according to their age and their parents, and on the other hand, the pediatric cardiologist who perform echocardiography before and after the treatment, and the analyzor has no information about the type of drug.The information for the two groups is provided as code A or B to the analyzer. 2-3 Persistent pulmonary hypertension of newborn. Intervention 1: Intervention group 1: Newborns with PPHN treated with Bosentan tablet 1mg/kg/dose every 12 hours through PG until 1 mounths. Intervention 2: Intervention group2 : Newborns with PPHN treated with sildenafil tablet 0.4 mg/kg/dose every 12 hours through PG until 1 mounths. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is After the study, the final decision is made